Dementia and Alzheimer Disease

April 16, 2021

The study presented at the 2021 AAN Meeting follows the complete response letter issued by the FDA to Acadia Pharmaceuticals due to deficiencies in their sNDA.

April 16, 2021

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 16, 2021.

April 16, 2021

Data from a cohort of more than 900 individuals suggest that while total tau can add cross-sectional value in certain contexts, neurofilament light served better for prognostication of cognitive decline and imaging changes.

April 16, 2021

The neurologist from Mayo Clinic discussed his abstract at AAN 2021 comparing stroke rates in patients with cerebral amyloid antipathy given treatment with aspirin.

April 14, 2021

The professor of health science at the Medical University of South Carolina detailed the limits of what can be achieved with behavioral interventions for the symptoms of dementia.

April 14, 2021

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.

April 14, 2021

Researchers analyzed data from the 10,472 Medicare beneficiaries diagnosed with mild cognitive impairment or dementia in California.

April 13, 2021

A group of 15 repurposed agents were identified as the best candidates for activity against the network of 20 related and distinct biochemical pathways that are dysregulated in AD-related dementia.

April 12, 2021

Here's what is coming soon to NeurologyLive.

April 10, 2021

The professor of health science at the Medical University of South Carolina spoke to the dire need for more therapeutic approaches to treat some of the most difficult symptoms of dementia.

April 10, 2021

Neurology News Network for the week ending April 10, 2021.

April 09, 2021

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed the issues that remain with enrolling patients into real-world dementia trials and standardizing measures.

April 09, 2021

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 9, 2021.

April 08, 2021

Researchers studied associations between CSF neurofilament light, neurogranin, and t-tau with measures of cortical thickness, white matter hyperintensities, and microstructural integrity.

April 06, 2021

Alzheimer disease-related neurodegeneration was correlated only with the thickness of the ganglion cell-inner plexiform layer.

April 05, 2021

There were no significant treatment group differences for measures of Alzheimer disease regional atrophy, cerebral blood flow, or mean fractional anisotropy.

April 05, 2021

The FDA cited a lack of statistical significance in some of the subgroups of dementia, and insufficient numbers of patients with certain less common dementia subtypes as lack of substantial evidence of effectiveness to support approval.

April 05, 2021

Here's what is coming soon to NeurologyLive.

April 03, 2021

Researchers found improvements in SIB and NPI score between high-dose and placebo groups.

April 02, 2021

Researchers on the FDA’s advisory committee conducted a review of the studies and evidence ahead of the treatment’s PDUFA date on June 7, 2021.